Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026)
Dyne Therapeutics' (DYN) quarterly Income from Continuing Operations came in at 165901000.0 in Q1 2026, down 28.92% year-on-year from 233394575.31 in Q1 2025, and down 85.77% on a QoQ basis from 89306000.0 in Q4 2025.
Dyne Therapeutics (DYN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 8 years of Income from Continuing Operations data on file, last reported at 165901000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 28.92% year-over-year to 165901000.0 in Q1 2026; TTM through Mar 2026 was 479401000.0, a 18.22% increase from a year earlier, with the FY2025 full-year figure at 491107000.0, up 22.36% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 165901000.0, down from 89306000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for DYN reached as high as 62515000.0 in Q1 2022 and fell as low as 250088000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 123660470.59 across 5 years, with a median of 104851000.0 in 2024.
- Across the five-year window, Income from Continuing Operations sank 198.27% in 2022 and jumped 53.67% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 153355000.0 in 2022, then sank by 42.66% to 218782000.0 in 2023, then soared by 53.12% to 102561000.0 in 2024, then rose by 12.92% to 89306000.0 in 2025, then sank by 85.77% to 165901000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 165901000.0 in Q1 2026, 89306000.0 in Q4 2025, and 108320000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | -165.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -165.90 Mn |
| Dec 31, 2025 | -89.31 Mn |
| Sep 30, 2025 | -108.32 Mn |
| Jun 30, 2025 | -115.87 Mn |
| Mar 31, 2025 | -128.69 Mn |
| Dec 31, 2024 | -102.56 Mn |
| Sep 30, 2024 | -104.85 Mn |
| Jun 30, 2024 | -250.09 Mn |
| Mar 31, 2024 | -202.78 Mn |
| Dec 31, 2023 | -218.78 Mn |
| Sep 30, 2023 | -77.74 Mn |
| Jun 30, 2023 | -93.05 Mn |
| Mar 31, 2023 | -77.32 Mn |
| Dec 31, 2022 | -153.36 Mn |
| Sep 30, 2022 | -84.65 Mn |
| Jun 30, 2022 | -66.46 Mn |
| Mar 31, 2022 | -62.52 Mn |
| Dec 31, 2021 | -51.41 Mn |
| Sep 30, 2021 | -103.44 Mn |
| Jun 30, 2021 | -124.92 Mn |